Orrick adds top Kramer Levin litigator
Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs.
Highly experienced litigator Irena Royzman has joined the life sciences team at Orrick in New York.
Most recently head of Kramer Levin’s life sciences practice, Royzman has for over 20 years represented pharmaceutical and biotechnology innovators on a wide range of critical cases, including involving small-molecule drugs, antibodies and other biologics, recombinant DNA technology, gene therapies, and medical devices.
Her record includes numerous multi-billion dollar cases involving many of the world’s best-selling drugs.
“Irena’s extraordinary scientific credentials and winning litigation record have earned the trust of the world’s leading life sciences companies,” said Alyssa Caridis, co-head of Orrick’s IP Business Unit. “We see her as another game-changing addition to our growing national team handling cutting-edge cases.”
Royzman has significant experience in litigation under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act. For plaintiffs, she has successfully defended challenges to patents protecting blockbuster HIV/AIDS, cancer and antipsychotic treatments.
For defendants, she obtained dismissal of all claims against a blockbuster retinal therapy.
She has also authored numerous amicus briefs to the US Supreme Court and Federal Circuit.
“Orrick is building the premier life sciences practice. I am excited by its commitment to the sector and helping life sciences innovators with their most novel and challenging matters,” said Royzman.
“Orrick’s trial culture, appellate prowess and holistic approach to serving the life sciences sector set the firm apart.”
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox
